Physicians can now order the Shield blood test through Quest's network of nearly 650,000 clinician and hospital accounts, patient service centers, and in-office phlebotomists.
Liquid biopsy may be used to improve the response to standard chemotherapy regimens in patients with stage III or stage II colon cancer.
Guardant Health is joining forces with leading patient advocacy groups to expand the Clear Your View initiative to raise awareness of the important role complete biomarker testing plays in guiding initial treatment decisions for newly diagnosed advanced colorectal cancer patients.
